Libtayo expansion

[anonymous]

Silence says all you need know.

 

[anonymous]

Libtato will be a bigger bust in NSCLC than Zalcrap was in CRC.

 

[anonymous]

Libtato will be a bigger bust in NSCLC than Zalcrap was in CRC.

Agreed. What is Regeneron thinking?

 

[anonymous]

Agreed. What is Regeneron thinking?

Look at our leaders.
These are the same people who made decision to dump the entire Praluent
Team. Overkill both ways

 

[anonymous]

Yawn

 

[anonymous]

We will know expansion plans in Nov. FDA will answer if fast tracked in lung or not. Regeneron wants to create a lung sleeve and an overlapping skin sleeve. More reps in same market with tiny Libtayo. The next Merck or BMS structure that will push all the good reps away.
Sell those options and cash in.

 

[anonymous]

The lung market does not need another PD1 checkpoint inhibitor unless it brings superior efficacy relative to currently available options.

ESMO data does not appear to demonstrate that degree of efficacy. It is after all metoovamab.

 

[anonymous]

We will know expansion plans in Nov. FDA will answer if fast tracked in lung or not. Regeneron wants to create a lung sleeve and an overlapping skin sleeve. More reps in same market with tiny Libtayo. The next Merck or BMS structure that will push all the good reps away.
Sell those options and cash in.

Why do you say sell those options?

 

[anonymous]

What is the final Libtayo expansion structure?
Expanding, esp during a pandemic is a joke.

 

[anonymous]

45 additional territories

 

[anonymous]

45 additional territories

with Covid shutting oncology reps out of more practices than any other disease state, with every company having oncology reps vying for time with the receptionist and with the current market perception of the product, is there a need for 45 additional reps?

 

[anonymous]

with Covid shutting oncology reps out of more practices than any other disease state, with every company having oncology reps vying for time with the receptionist and with the current market perception of the product, is there a need for 45 additional reps?

Um, no..........

 

[anonymous]

Um, no..........

Think Son of Zalcrap.

 

[anonymous]

Anyone with a dose of common sense knows what will happen here.

 

[anonymous]

Anyone with a dose of common sense knows what will happen here.

Let's predict. I'll start. We get our @$$es handed to us and then downsizing/layoffs.

 

[HQ worker bee]

real answers
Why do Sanofi and Libtayo management dislike each other? How do you expect the sales teams to produce results with our leaders acting like spoiled children in the sandbox fighting for the spotlight and credit?

They don't dislike each other they are just working from monumentally different incentive structures. Also Len exerts outsize influence on commercial.

 

[anonymous]

They don't dislike each other they are just working from monumentally different incentive structures. Also Len exerts outsize influence on commercial.

Outsized influence? Marionette, oops I mean Marion, does exactly as she is told.

 

[anonymous]

Regeneron stumbles in PhI Libtayo combo study as safety concerns force suspension.

Metoomavab is going to have to make it on its own.